Clinical Physiology of Circulation

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, Director of Bakoulev National Medical Research Center for Cardiovascular Surgery

Biomarkers in atrial fibrillation

Authors: F.R. Akildzhonov, Yu.I. Buziashvili, E.U. Asymbekova

Bakoulev National Medical Research Center for Cardiovascular Surgery, Moscow, 121552, Russian Federation

E-mail: Сведения доступны для зарегистрированных пользователей.


UDC: 616.125

Link: Clinical Physiology of Blood Circulaiton. 2020; 17 (3): 195-202

Quote as: Akildzhonov F.R., Buziashvili Yu.I., Asymbekova E.U. Biomarkers in atrial fibrillation. Clinical Physiology of Circulation. 2020; 17 (3): 195–202 (in Russ.). DOI: 10.24022/1814-6910-2020-17-3-195-202

Received / Accepted:  06.05.2020/18.05.2020

Full text:
Subscribe 🔒


Atrial fibrillation (AF) is the most commonly reported heart rhythm disorder and has a significant impact on morbidity, disability, and death in the population. Identifying biological markers improved our understanding of the AF mechanism and demonstrated the ability to improve AF risk stratification. Currently, biomarkers have significantly improved risk stratification in addition to current models for predicting risk in patients with atrial fibrillation. The same results were observed for markers of kidney function, markers of blood clotting, and markers of inflammation in patients with atrial fibrillation based on large randomized clinical trials. This data may allow the development of new tools to improve risk stratification in patients with AF. In this review, presented data from current clinical studies on biomarkers in patients with AF, highlight new associations of biomarkers, discuss their potential benefits for selecting optimal treatment strategies to prevent thromboembolic complications, mortality, and bleeding during anticoagulant therapy, and discuss progress in using biomarkers to stratify risk in patients with AF.


  1. Бокерия Л.А., Шенгелия Л.Д. Лечение фибрилляции предсердий. Часть I. Долгий путь к «золотому стандарту». Анналы аритмологии. 2014; 11 (2): 64–76. DOI: 10.15275/annaritmol.2014.2.1 [Bockeria L.A., Shengeliya L.D. Treatment of atrial fibrillation. Part I. Long way to the gold standart. Annaly Aritmologii. 2014; 11 (2): 64–76 (in Russ.). DOI: 10.15275/annaritmol.2014.2.1] 
  2. Бокерия Л.А., Базаев В.А., Филатов А.Г., Меликулов А.Х., Висков Р.В., Грицай А.Н. Изолированная форма фибрилляции предсердий. Анналы аритмологии. 2006; 2: 39–47. [Bockeria L.A., Bazaev V.A., Filatov A.G., Melikulov A.Kh., Viskov R.V., Gritsay A.N. Lone atrial fibrillation. Annaly Aritmologii. 2006; 2: 39–47 (in Russ.).] 
  3. Hijazi Z., Oldgren J., Siegbahn A., Granger C.B., Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur. Heart J. 2013; 34: 1475–80. DOI: 10.1093/ eurheartj/eht024 
  4. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J., Coats A. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2016; 37 (27): 2129–200. DOI: 10.1093/ eurheartj/ehw128 
  5. Ibanez B., James S., Agewall S., Antunes M., Bucciarelli-Ducci C., Bueno H. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2017; 39 (2): 119–77. DOI: 10.1093/eurheartj/ehx393 
  6. Goette A., Kalman J. M., Aguinaga L., Akar J., Cabrera J., Chen S. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterisation, and clinical implication. J. Arrhythmia. 2016; 32 (4): 247–78. DOI: 10.1016/j.joa.2016. 05.002 
  7. Жолбаева А.З., Табина А.Е., Голухова Е.З. Молекулярные механизмы фибрилляции предсердий: впоиске«идеального» маркера. Креативная кардиология. 2015; 9 (2): 40–1. DOI: 10.15275/kreatkard.2015.02.04 [Zholbaeva A.Z., Tabina A.E., Golukhova E.Z. Molecular mechanisms of atrial fibrillation: “ideal” marker searching. Creative Cardiology. 2015; 9 (2): 40–1 (in Russ.). DOI: 10.15275/kreatkard.2015.02.04] 
  8. Silvet H., Young-Xu Y., Walleigh D., Ravid S. Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am. J. Cardiol. 2003; 92 (9): 1124–7. DOI: 10.1016/j.amjcard.2003.07.010 
  9. Breidthardt T., Noveanu M., Cayir S., Viglino M., Laule K., Hochholzer W. The use of B-type natriuretic peptide in the management of patients with atrial fibrillation and dyspnea. Intern. J. Cardiol. 2009; 136 (2): 193–9. DOI: 10.1016/j.ijcard.2008.04.045 
  10. Goetze J.P., Friis-Hansen L., Rehfeld J.F., Nilsson B., Svendsen J.H. Atrial secretion of B-type natriuretic peptide. Eur. Heart J.2006; 27 (14): 1648–50. DOI: 10.1093/ eurheartj/ehl109 
  11. Christersson Ch. Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. Heart (British Cardiac Society). 2019; 105 (3): 235–42. DOI:10.1136/heartjnl-2018-313351 
  12. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A. et al.; the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009; 361: 1139–51. DOI: 10.1056/NEJMoa0905561 
  13. Göldi T., Krisai Ph., Knecht S., Aeschbacher S., Spies F., Zeljkovic I. Prevalence and management of atrial thrombi in patients with atrial fibrillation before pulmonary vein isolation. JACC Clin. Electrophysiol. 2019; 5 (12): 1406–14. DOI: 10.1016/j.jacep.2019.09.003 
  14. Frustaci A., Chimenti C., Bellocci F., Morgante E., Russo M.A., Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997; 96: 1180–4. DOI: 10.1161/01.cir. 96.4.1180 
  15. Frustaci A., Caldarulo M., Buffon A., Bellocci F., Fenici R., Melina D. Cardiac biopsy in patients with “primary” atrial fibrillation: histologic evidence of occult myocardial diseases. Chest. 1991; 100: 303–6. DOI: 10.1161/01.CIR.96.4.1180 
  16. Issac T.T., Dokainish H., Lakkis N.M. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J. Am. Coll. Cardiol. 2007; 50: 2021–8. DOI: 10.1016/j.jacc. 2007.06.054 
  17. Conway D.S., Buggins P., Hughes E., Lip G.Y. Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transesophageal echocardiographic findings in atrial fibrillation. Am. J. Cardiol. 2004; 93: 1368–73. DOI:10.1016/j.jacc.2003.11.062 
  18. Григорян С.В., Адамян К.Г., Азарапетян Л.Г. Роль маркеров воспаления при фибрилляции предсердий (обзор). Кардиоваскулярная терапия и профилактика. 2012; 11 (5): 74–8. DOI: 10.15829/17288800-2012-5-74-78 [Grigoryan S.V., Adamyan K.G., Azarapetyan L.G. The role of inflammatory markers in atrial fibrillation: a review. Cardiovascular Therapy and Prevention. 2012; 11 (5): 74–8 (in Russ.). DOI: 10.15829/1728-88002012-5-74-78] 
  19. Guo Y., Lip G.Y., Apostolakis S. Inflammation in atrial fibrillation. J. Am. Coll. Cardiol. 2012; 60: 2263–70. DOI: 10.1016/j.jacc.2012.04.063 
  20.  Park B., Choe E., Kang H., Shin E., Lee S., Won C. Genetic polymorphisms associated with the neutrophillymphocyte ratio and their clinical implications for metabolic risk facrors. J. Clin. Med. 2018; 7 (8): 204. DOI: 10.3390/jcm7080204 
  21. Conway D.S., Buggins P.S., Hughes E., Lip G.Y. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am. Heart J. 2004; 148: 462–6. DOI: 10.1016/j.ahj. 2004.01.026 
  22.  Roldan V., Marin F., Diaz J., Gallego P., Jover E., Romera M. et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J. Thromb. Haemost. 2012; 10: 1500–7. DOI: 10.1111/j.1538-7836.2012.04812.x 
  23. Hermida J., Lopez F.L., Montes R., Matsushita K., Astor B.C., Alonso A. Usefulness of high-sensitivity C-reactive protein to predict mortality in patients with atrial fibrillation (from the Atherosclerosis Risk in Communities (ARIC) Study). Am. J. Cardiol. 2012; 109 (1): 95–9. DOI:10.1016/j.amjcard. 2011.08.010 
  24. Lip G.Y., Patel J.V., Hughes E., Hart R.G. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke. 2007; 38: 1229–37. DOI: 10.1161/01.STR.0000260090.90508.3e 
  25. Sharma S., Jackson P. G., Makan J. Cardiac troponins. J. Clin. Pathol. 2004; 57 (10): 1025–6. DOI: 10.1136/ jcp.2003.015420 
  26. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J.2015; 37 (3): 267–315. DOI: 10.1093/eurheartj/ehv320 
  27. Van den Bos E.J., Constantinescu A.A., van Domburg R.T., Akin S., Jordaens L.J., Kofflard M.J.M. Minor elevations in troponin I are associated with mortality and adverse cardiac events in patients with atrial fibrillation. Eur. Heart J. 2011; 32 (5): 611–7. DOI: 10.1093/eurheartj/ehq491 
  28. Eggers K.M., Lind L., Ahlstrom H., Bjerner T., Ebeling Barbier C., Larsson A. et al. Prevalence and pathophysiological mechanisms of elevated cardiac troponin I levels in a population-based sample of elderly subjects. Eur. Heart J. 2008; 29: 2252–8. DOI: 10.1093/eurheartj/ehn327 
  29. Jeremias A., Gibson C.M. Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann. Intern. Med. 2015; 142: 786–91. DOI: 10.7326/0003-4819-142-9200505030-00015 
  30. Providencia R., Paiva L., Faustino A., Botelho A., Trigo J., Casalta-Lopes J. et al. Cardiac troponin I: prothrombotic risk marker in nonvalvular atrial fibrillation. Int. J. Cardiol. 2013; 167: 877–82. DOI: 10.1161/ STROKEAHA.115.008681 
  31. Takashio S., Yamamuro M., Izumiya Y., Sugiyama S., Kojima S., Yamamoto E. et al. Coronary microvascular dysfunction and diastolic load correlate with cardiac troponin T release measured by a highly sensitive assay in patients with nonischemic heart failure. J. Am. Coll. Cardiol. 2013; 62: 632–40. DOI: 10.1016/j.jacc.2013.03.065 
  32. Hussein A.A., Bartz T.M., Gottdiener J.S., Sotoodehnia N.N., Heckbert S.R. Serial measures of cardiac troponin T levels by a highly sensitive assay and incident atrial fibrillation in a prospective cohort of ambulatory older adults. Heart Rhythm. 2015; 12 (5): 879–85. DOI: 10.1016/j.hrthm.2015.01.020 
  33. Ford I., Shah A.S.V., Zhang R., McAllister D., Strachan F., Caslake M. High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease. J. Am. Coll. Cardiol. 2016; 68 (25): 2719–28. DOI: 10.1016/ j.jacc.2016.10.020 
  34. Connolly S., Ezekowitz M., Yusuf S., Eikelboom J., Oldgren J., Parekh A. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009; 361: 1139–51. DOI: 10.1056/NEJMoa0905561
  35. Hijazi Z., Oldgren J., Andersson U., Connolly S.J., Ezekowitz M.D., Hohnloser S.H. et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a RandomizedEvaluation of Long-Term Anticoagulation Therapy [RE-LY] sub-study. Circulation. 2012; 125: 1605–16. DOI: 10.1161/CIRCULATIONAHA.111.038729 
  36. Leal J.C., Petrucci O., Godoy M.F., Braile D.M. Perioperative serum troponin I levels are associated with higher risk for atrial fibrillation in patients undergoing coronary artery bypass graft surgery. Interact. Cardiovasc. Thorac. Surg. 2012; 14 (1): 22–5. DOI: 10.1093/ icvts/ivr019 
  37. Clementy N., Piver E., Bisson A., Andre C., Bernard A., Pierre B. et al. Galectin-3 in atrial fibrillation: mechanism and therapeutic implications. Int. J. Mol. Sci. 2018; 19 (4): 976. DOI: 10.3390/ijms19040976 
  38. Ho J., Liu C., Lyass A., Courchesne P., Pencina M.J., Vasan R. et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J. Am. Coll. Cardiol. 2012; 60: 1249–56. DOI: 10.1016/j.jacc. 2012.04.053 
  39. Shah R., Chen-Tournoux A., Picard M., van Kimmenade R., Januzzi J. Galectin-3, cardiac structure and function, and longterm mortality in patients with acutely decompensated heart failure. Eur. J. Heart Fail. 2010; 12: 826–32. DOI: 10.1093/eurjhf/hfq091 
  40. Gong Mengqi, Cheung Angel, Wang Qun-Shan, Li Guangping, Goudis Christos, Bazoukis George. Galectin-3 and risk of atrial fibrillation: a systematic review and meta-analysis. J. Clin. Lab. Analys. 2020; 197: 853–9. DOI: 10.1002/jcla.23104 
  41. Knight E., Verhave J., Spiegelman D., Hillege H., de Zeeuw D., Curhan G., de Jong P. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004; 65: 1416–21. DOI: 10.1111/j.1523-1755.2004. 00517.x 
  42. Newman D.J., Thakkar H., Edwards R.G., Wilkie M., White T., Grubb A.O., Price C.P. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int. 1995; 47: 312–8. DOI: 10.1038/ki.1995.40 
  43. Imai A., Komatsu S., Ohara T., Kamata T., Yoshida J., Miyaji K. et al. Serum cystatin C is associated with early stage coronary atherosclerotic plaque morphology on multidetector computed tomography. Atherosclerosis. 2011; 218: 350–5. DOI: 10.4330/wjc.v9.i2.174 
  44. Hijazi Z., Hohnloser S., Oldgren J., Andersson U., Connolly S.J., Eikelboom J. et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis. Circulation. 2014; 129: 961–70. DOI: 10.1016/j.ahj.2017.10.015 
  45. Wang J., Sim A., Wang X., Salonikas C., Moriatis M., Naidoo D., Wilcken D. Relations between markers of renal function, coronary risk factors and the occurrence and severity of coronary artery disease. Atherosclerosis. 2008; 197: 853–9. DOI: 10.1186/1475-2840-11-108 
  46. Vischer U.M. Von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J. Thromb. Haemost.2006; 4: 1186–93. DOI: 10.1111/j.1538-7836. 2006.01949.x 
  47. Fukuchi M., Watanabe J., Kumagai K., Katori Y., Baba S., Fukuda K. et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J. Am. Coll. Cardiol. 2001; 37: 1436–42. DOI: 10.1016/ s0735-1097[01]01125-1 
  48. Alonso A., Tang W., Agarwal S.K., Soliman E.Z., Chamberlain A.M., Folsom A.R. Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: the ARIC study. Int. J. Cardiol. 2012; 155: 217–22. DOI: 10.1016/j.ijcard.2010.09.051 
  49. Conway D., Pearce L., Chin B., Hart R., Lip G. Prognostic value of plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation. 2003; 107: 314–5. DOI: 10.1161/01.CIR.0000077912.12202.FC 
  50. Бокерия Л.А., Голухова Е.З., Кочладзе Н.Г., Макаренко В.Н., Александрова С.А., Серов Р.А. Прогностическое и клиническое значение маркеров ремоделирования предсердий при фибрилляции предсердий. Анналы аритмологии.2004; 1: 71–7. [Bockeria L.A., Golukhova E.Z., Kochladze N.G., Makarenko V.N., Aleksandrova S.A., Serov R.A. Prognostic and clinical significance of atrial remodeling markers in atrial fibrillation. Annaly Aritmologii.2004; 1: 71–7 (in Russ.).] 
  51. Sadanaga T., Sadanaga M., Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J. Am. Coll. Cardiol. 2010; 55: 2225–31. DOI: 10.1016/j.jacc.2009.12.049 
  52. Vene N., Mavri A., Kosmelj K., Stegnar M. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb. Haemost. 2003; 90: 1163–72. DOI: 10.1160/TH03-06-0363 
  53. Lip G.Y., Lowe G.D., Rumley A., Dunn F.G. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br. Heart J. 1995; 73: 527–33. DOI: 10.1136/hrt.73.6.527 
  54. Becker R., Alexander J., Newby L., Yang H., Barrett Y., Mohan P. Effect of apixaban, an oral anddirect factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb. Haemost. 2010; 104 (5): 976–83. DOI: 10.1160/TH10-04-0247 
  55. Siegbahn A., Oldgren J., Andersson U., Ezekowitz M., Reilly P., Connolly S. D-dimer and factor VIIA in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy. Thromb. Haemost. 2016; 115. DOI: 10.1160/ TH15-07-0529 
  56. Pisters R., Lane D.A., Nieuwlaat R., de Vos C.B., Crijns H.J., Lip G.Y. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138 (5): 1093–100. DOI: 10.1378/ chest.10-0134 
  57.  Schmidt M., Rieber J., Daccarett M., Marschang H., Sinha A.M., Biggar P. et al. Relation of recurrence of atrial fibrillation after successful cardioversion to renal function. Am. J. Cardiol. 2010; 105: 368–72. DOI: 10.1111/j.1540-8167.2011.02069.x

About Authors

  • Firdavsdzhon R. Akildzhonov, Resident Physician; 
  • Yuriy I. Buziashvili, Dr. Med. Sc., Professor, Academician of the Russian Academy of Sciences, Head of Clinical and Diagnostic Department; 
  • El'mira U. Asymbekova, Dr. Med. Sc., Leading Researcher;

 If you found mistakes, select text and press Alt+A